MX2 protein (purple) interacting with a Transportin-1 protein (cyan) in a living cell.
MX2 protein (purple) interacting with a Transportin-1 protein (cyan) in a living cell.

Scientists discover viral trapdoor blocking HIV and herpes

Ghent, 10 October 2024 – A group of researchers led by Xavier Saelens and Sven Eyckerman at the VIB-UGent Center for Medical Biotechnology discovered how a protein linked to the human immune system wards off HIV-1 and herpes simplex virus-1 by assembling structures in the cell that lure in these viruses and then trap them or even take them apart. The research was spearheaded by first author George Moschonas, published in Cell Host and Microbe, and could be used to devise new strategies to combat these viruses.

The innate immune system of the human body can sense and respond to viruses by producing alarm cytokines, most notably interferons. These proteins act as an alarm system that goes off when a cell is infected by a virus, warning surrounding cells of an invasion and prompting them to activate their antiviral defenses. These defenses comprise so-called interferon-stimulated genes (ISGs), which produce specific proteins with antiviral qualities. One example of this is the MX protein, which was discovered 60 years ago and restricts a broad range of viruses, including those that cause AIDS and herpes.

To date, researchers were unsure how the antiviral properties of the MX protein worked. However, in this new study led by Xavier Saelens and Sven Eyckerman of the VIB-UGent Center for Medical Biotechnology and in collaboration with Beate Sodeik (Hannover Medical School), Zeger Debyser (KU Leuven), Linos Vanderkerckhove (UGent) and Nico Callewaert (VIB-UGent), the secret of the MX protein’s antiviral activity was uncovered.

A virus decoy

A herpes or HIV virus delivers its genome in the host cell nucleus through the nuclear pore complex. This delivery is essential for the virus to launch its genetic program, hijack the cell’s machinery and propagate. As a result, new viruses are made, that leave the cell and spread to surrounding cells.

In an illuminating discovery, the researchers show how the MX protein drives the assembly of virus decoy structures that mimic nuclear pore complexes.

Sven Eyckerman: “We noticed that incoming viruses were being lured into structures that resembled nuclear pores. Through proteomics screens, we found that the MX protein interacts with proteins that are part of the nuclear pore complex. On closer inspection, we discovered that the MX protein orchestrates the assembly of nucleoporins into biomolecular condensates, membrane-less droplets inside a cell that act like a separate compartment. Viruses mistake these condensates for the actual cell door to the cell nucleus and get trapped or punctured.”
MX2 condensates (purple) trapping HIV-1 particles (orange and green).
MX2 condensates (purple) trapping HIV-1 particles (orange and green).
Xavier Saelens: “By tricking viruses into prematurely releasing their genetic material, the MX protein ultimately prevents the spread of viral infections. This discovery not only clarifies how MX proteins combat viruses but also opens up potential new avenues for antiviral therapies.”

—

Moschonas et al. MX2 forms nucleoporin-comprising cytoplasmic biomolecular condensates that lure viral capsids

DOI: 10.1016/j.chom.2024.09.002

The research described in this study was made possible thanks to financial support from FWO, the German Research Council and ERC.

—

Joran Lauwers

Joran Lauwers

Press Contact, VIB

About the VIB-UGent Center for Medical Biotechnology

Research at the VIB-UGent Center for Medical Biotechnology can lead to more effective medicine. If we know the causes and mechanisms of a disease, we can then deal with it in a better way. This is much more efficient than treating the symptoms, which is how things are often done at the moment. The research helps to prevent, diagnose or treat diseases.

Share

Latest stories

An inside look at a molecular switch that triggers inflammation

An inside look at a molecular switch that triggers inflammation

Ghent, 9 November 2026 – Researchers at VIB and Ghent University have uncovered how an important driver of inflammation is activated at the molecular level. Their findings, published in Science Immunology, also explain how a medicine used to treat a severe form of psoriasis blocks this inflammatory signal.

press.vib.be

Researchers uncover why humans are more sensitive than other species to a brain developmental disease

Researchers uncover why humans are more sensitive than other species to a brain developmental disease

Leuven, 4 November 2026 – Researchers at VIB and KU Leuven have uncovered how mutations in the ASPM gene disrupt the development of neural stem cells that help the human brain grow. This disruption explains how these mutations cause microcephaly, a condition characterized by an abnormally small brain and head, often accompanied by intellectual disability. The discovery, published in Developmental Cell, also sheds light on how differences in brain development can make humans more susceptible to certain genetic conditions than other mammals.

press.vib.be

How blocking immune cell signals could make brain tumors easier to remove

How blocking immune cell signals could make brain tumors easier to remove

Leuven, Belgium, 27 October 2026 – In a new study published in Cancer Cell, researchers at VIB-KU Leuven reduced the spread of glioblastoma by interrupting specific interactions between the brain’s immune cells and tumor cells. The discovery points to a possible new therapeutic strategy, in which blocking communication between immune and cancer cells makes tumors more contained and easier to remove.

press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be